The Covid-19 pandemic turned Chinese vaccine-maker Sinovac Biotech Ltd. into a global household name after its CoronaVac jab became a billion-dollar money-spinner and one of the world’s most-administered inoculations against the virus. But hidden away behind its success lies a bitter, decade-long power struggle for control of the company.
In Depth: Sinovac’s Covid Fortune Fuels Bitter Boardroom Battle
2025年07月23日 13:47
A legal fight across three countries has left its shares suspended on the Nasdaq for six years and $10 billion of cash stuck in the bank
[财新双语通产品，是为有双语需求读者专门订制的优惠产品， 按此可享超值优惠订阅。]
版面编辑：喻竹杨洋
图片推荐
编辑推荐
最新文章
- 14:00三一重能拉美负责人：巴西下一轮新能源增长机遇在2027年前后｜出海·能源
- 13:30【商旅对话】陪伴式赋能·数智化远航：蒙泰与IBM共解传统产业“转型+出海”双重命题
- 12:58人畜无害：宠物投毒案背后的争议
- 12:24下半年AI相关人才供过于求 岗位变化反映AI技术落地应用加速
- 12:09权色钱色交易+干预插手执法 江西高官胡幼桃被开除党籍移送司法
- 12:04利用药品注册审批谋利 国家中医药管理局原局长于文明被移送司法
- 12:01多家银行关闭“三无”客户上金所贵金属业务功能 所为何因？
- 11:46干细胞治疗，能否真正“返老还童”
- 10:46天津一股权转让案判决生效逾四年启动再审 “院长发现程序”引争议
- 10:38情绪指标看牛市到了哪一步
京公网安备 11010502034662号 
